Kazia Therapeutics Ltd - Company Profile
Powered by 
All the sales intelligence you need on Kazia Therapeutics Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Kazia Therapeutics Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Kazia Therapeutics Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Kazia Therapeutics Ltd (Kazia) is a clinical-stage biotechnology company. It focuses on the discovery and development of anti-cancer drugs. The company’s product pipeline includes paxalisib (formerly GDC-0084), Cantrixil (TRX-E-002-1) and EVT801. Paxalisib is an inhibitor of the PI3K /AKT /mTOR pathway to treat glioblastoma multiforme It is in phase II clinical trials. TRX-E-002-1 (Cantrixil) is a third-generation benzopyran molecule that acts against cancer stem cells. Cantrixil is in phase I clinical trials for the treatment of ovarian cancer. EVT801 is a substance that blocks a cellular receptor called VEGFR3, which is responsible for the development of new blood and lymphatic vessels. The company has collaborations with various research institutes, hospitals, and universities, including St Jude Children's Hospital, University of Newcastle, Dana Farber Cancer Institute and Memorial Sloan Kettering Cancer Centre to develop its pipeline. Kazia is headquartered in Sydney, New South Wales, Australia.
Headquarters
Australia
Address
Three International Towers Level 24, , 300 Barangaroo Avenue, Sydney, New South Wales, 2000
Website
www.kaziatherapeutics.com
Telephone
61 2 94724100
No of Employees
12
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KZIA (NASD)
Revenue (2024)
$75,200
-95.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
22.7%
(2024 vs 2023)
Market Cap*
$167.9M
Net Profit Margin (2024)
XYZ
-1,473.3%
(2024 vs 2023)
* As of and is in US$
Kazia Therapeutics Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Products |
| Pipeline: |
| Paxalisib (GDC-0084): Glioblastoma Multiforme, Brain Metastases, Breast Cancer and Diffuse Intrinsic Pontine Glioma |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Divestiture | In March, the company sold its intellectual property and trademark rights for Cantrixil, an oncology drug candidate, to Vivesto for US$1 million. |
| 2024 | Contracts/Agreements | In September, the company agreed with QIMR Berghofer Medical Research Institute to obtain an exclusive license to certain intellectual property rights about combination therapies consisting of PI3K inhibitor drugs, and one or more immunotherapy or PARP inhibitor drugs (PI3K combination). |
| 2024 | Contracts/Agreements | In March, the company entered into an exclusive licensing agreement with Sovargen Co Ltd to develop, manufacture and commercialise paxalisib as a potential treatment o f intractable epilepsy in focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC) disease. |
Competitor Comparison
| Key Parameters | Kazia Therapeutics Ltd | Amgen Inc | Blueprint Medicines Corp | Noxopharm Ltd | Mereo Biopharma Group Plc |
|---|---|---|---|---|---|
| Headquarters | Australia | United States of America | United States of America | Australia | United Kingdom |
| City | Sydney | Thousand Oaks | Cambridge | Sydney | London |
| State/Province | New South Wales | California | Massachusetts | New South Wales | England |
| No. of Employees | 12 | 31,500 | 649 | 1,000 | 39 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dr. John Friend | Chief Executive Officer; Managing Director | Executive Board | 2023 | - |
| Sudha Rao | Chief Scientific Officer | Senior Management | 2026 | - |
| Bryce Carmine | Chairman | Non Executive Board | 2024 | - |
| Jeffrey Bonacorda | Vice President - Finance; Controller | Senior Management | 2024 | - |
| Elissa Hansen | Secretary | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer